Main Menu

About NewSTEPs
Newborn Screening Disorders
- Case Definitions
Resource Library
- Toolkits
- Webinars & Events
Data Center
- NBS Cases
- Quality Indicators
- State Profiles
- Dashboards and Reports
- Request Data
Manage Data
- User Management
- Submit Confirmed Case Data
- Submit Quality Indicator Data
- Submit State Profile Data
- Data Dictionary

NewSTEPs
Resource Library
X-Linked Adrenoleukodystrophy (X-ALD) Clinical Considerations: New Disorders Meeting June, 2017

X-Linked Adrenoleukodystrophy (X-ALD) Clinical Considerations: New Disorders Meeting June, 2017

Date: June 22, 2017

This is a presentation provided by Paul Orchard, MD during the new disorders meeting in June, 2017, describing the clinical considerations for screening for X-Linked Adrenoleukodystrophy (X-ALD).

ALD Clinical Considerations

Related Resources

Educational Tools

Action Guide for Accelerating Improvement in Cystic Fibrosis Care (CF)

January 01, 2006

Publications

Emergency Preparedness for Newborn Screening (NBS) and Genetic Services

June 01, 2009

Publications

Strategies for Implementing Screening for Critical Congenital Heart Disease (CCHD)

November 01, 2011

Outdated Browser

This website is not compliant with Internet Explorer. Please continue your experiense using Microsoft Edge, or another up-to-date browser.

This resource, a program of APHL, was developed by funding from the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under grant number U22MC24078 for $2,725,000.

Follow

newsteps@aphl.org

X-Linked Adrenoleukodystrophy (X-ALD) Clinical Considerations: New Disorders Meeting June, 2017

Tags

Share

Related Resources

Educational Tools

Publications

Publications

Outdated Browser